Neda Razavi is CEO of iSono Health, where she's leading the shift of breast ultrasound from a specialist ski l into something as ordinary as a blood pressure check — no sonographer required, no specialist suite. She backed the company early, as a seed investor, before it had FDA clearance; she took over as CEO because she believed the technology deserved a faster path to patients than the one it was on. Her path includes 26 years in medtech and diagnostics at Ilumina, Roche, Abbott Laboratory, Medtronic, Natera, and Kythera (Alergan), Baxter BioScience (Takeda), where she's launched 65 products across seven platforms, work that touched areas from genomic sequencing to coagulation testing to Type II diabetes care. Trained as a celular microbiologist with an MBA in finance and advance degree in Genetics and Genomics, she's spent her career at the point where hard science must become something a clinic can actualy use. She's also a single mother of three, raising two daughters in a country where a third of women skip their breast screening entirely. That's not a footnote to her work — it's most of the reason for it. She wants her daughters to inherit a healthcare system where early detection isn't a privilege you have to know how to access.